Annika Pasanen

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.

Journal: Lancet (London, England)
Published: February 18, 2025

Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma.

Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma.

Journal: Blood advances
Published: January 02, 2025

Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial.

Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial.

Journal: HemaSphere
Published: December 01, 2024

Biomarker-adapted treatment in high-risk large B-cell lymphoma.

Biomarker-adapted treatment in high-risk large B-cell lymphoma.

Journal: HemaSphere
Published: November 29, 2024

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.

Journal: Blood advances
Published: October 12, 2023

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.

Journal: Cell reports. Medicine
Published: April 19, 2023

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.

Journal: Blood
Published: June 07, 2021

Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.

Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 16, 2020

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.

Journal: Blood advances
Published: February 25, 2020

Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series.

Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series.

Journal: Blood advances
Published: December 09, 2019

Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.

Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.

Journal: Leukemia
Published: January 16, 2019

Clinical significance of gene defects in B-cell lymphomas.

Clinical significance of gene defects in B-cell lymphomas.

Journal: Duodecim; laaketieteellinen aikakauskirja
Published: December 15, 2017
Showing 1-12 of 14

Last Updated: 09/26/2026